Patents by Inventor Stephen J. Hoffman
Stephen J. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6894185Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.Type: GrantFiled: September 10, 2002Date of Patent: May 17, 2005Assignee: Allós Therapeutics, Inc.Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
-
Patent number: 6828125Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.Type: GrantFiled: May 30, 1995Date of Patent: December 7, 2004Assignee: Baxter Biotech Technology, S.a.r.l.Inventors: Stephen J. Hoffman, Douglas L. Looker, Kiyoshi Nagai
-
Publication number: 20030130523Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.Type: ApplicationFiled: September 10, 2002Publication date: July 10, 2003Inventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
-
Patent number: 6534501Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).Type: GrantFiled: March 7, 2001Date of Patent: March 18, 2003Assignees: Allos Therapeutics, Inc., Virginia Commonwealth UniversityInventors: Donald J. Abraham, Changging Wang, Richmond Danso-Danquah, James C. Burnett, Gajanan S. Joshi, Stephen J. Hoffman
-
Patent number: 6486342Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.Type: GrantFiled: August 23, 2000Date of Patent: November 26, 2002Assignee: Virginia Commonwealth UniversityInventors: Donald J. Abraham, Gajanan S. Joshi, Stephen J. Hoffman, Melissa Grella, Richmond Danso-Danquah, Amal Yousseff, Martin Safo, Sanjeev Kulkarni
-
Publication number: 20020025791Abstract: A preferred embodiment of the present invention generally comprises a hand-held two-way radio employing digital selective calling. The hand-held two-way radio further comprises a VCO operative to modulate the radio signal frequencies of a guard channel such that the guard channel can be changed by changing the output of the VCO. In addition, the present invention comprises a hand-held two-way radio comprising circuitry operative to function according to the digital selective calling international standards, and a VCO operative to modulate the radio signal frequencies of a guard channel such that the guard channel can be changed by changing the output of the VCO. A fourth embodiment of the present invention comprises a hand-held two-way radio comprising circuitry operative to send and receive GPS data, and a VCO operative to modulate the radio signal frequencies of a guard channel such that the guard channel can be changed by changing the output of the VCO.Type: ApplicationFiled: March 20, 2001Publication date: February 28, 2002Inventors: John W. Englert, Stephen J. Hoffman
-
Patent number: 6214879Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate.Type: GrantFiled: March 24, 1998Date of Patent: April 10, 2001Assignee: Virginia Commonwealth UniversityInventors: Donald J. Abraham, Richmond E. Danso-Danquah, Telih Boyiri, Changquing Wang, Michael J. Gerber, Stephen J. Hoffman, Gajanan Joshi
-
Patent number: 6124114Abstract: Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes.Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen.Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha glolbin gene was substantially improved by means of a beta globin gene "header".Type: GrantFiled: May 26, 1995Date of Patent: September 26, 2000Assignee: Baxter Biotech Technology SarlInventors: Stephen J. Hoffman, Kiyoshi Nagai
-
Patent number: 5844088Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.We further describe the production of tetrameric human hemoglobin and di-alpha/beta.sub.2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site.Type: GrantFiled: May 19, 1995Date of Patent: December 1, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
-
Patent number: 5844089Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.Type: GrantFiled: May 25, 1995Date of Patent: December 1, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
-
Patent number: 5798227Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.We further describe the production of tetrameric human hemoglobin and di-alpha/beta.sub.2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site.Type: GrantFiled: May 19, 1995Date of Patent: August 25, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Gary L. Stetler, Michael Wagenbach
-
Patent number: 5776890Abstract: Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes. Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen. Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".Type: GrantFiled: May 30, 1995Date of Patent: July 7, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Kiyoshi Nagai
-
Patent number: 5744329Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.Type: GrantFiled: May 19, 1995Date of Patent: April 28, 1998Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Mary S. Rosendahl, Gary L. Stetler, Michael Wagenbach, David C. Anderson, Antony James Mathews, Kiyoshi Nagai
-
Patent number: 5661124Abstract: The present invention provides blood substitutes comprised of recombinantly produced mutant hemoglobin having an osmolarity greater than 303 milliosmoles per liter and less than 800 milliosmoles per liter. Such hyperosmolar blood substitute additionally comprises a physiologically acceptable molecule less diffusible than dextrose.Type: GrantFiled: March 1, 1995Date of Patent: August 26, 1997Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Kiyoshi Nagai
-
Patent number: 5563254Abstract: The present invention provides for polynucleotides capable of producing recombinant hemoglobins that have a P.sub.50 of 26-36 torr. This invention makes possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form, which can be used as blood substitutes.Type: GrantFiled: December 20, 1993Date of Patent: October 8, 1996Assignees: Medical Research Council, Somatogen, Inc.Inventors: Stephen J. Hoffman, Kiyoshi Nagai
-
Patent number: 5545727Abstract: The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.DNA encoding alpha globin fusion proteins is provided.Type: GrantFiled: November 8, 1991Date of Patent: August 13, 1996Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Douglas L. Looker, Kiyoshi Nagai
-
Patent number: 5525630Abstract: Allosteric hemoglobin modifier compounds are disclosed that clear carbon monoxide hemoglobin from a host animal.Type: GrantFiled: June 1, 1995Date of Patent: June 11, 1996Assignee: Allos Therapeutics, Inc.Inventor: Stephen J. Hoffman
-
Patent number: 5449759Abstract: Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes.Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen.Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".Type: GrantFiled: November 29, 1993Date of Patent: September 12, 1995Assignee: Somatogen, Inc.Inventors: Stephen J. Hoffman, Kiyoshi Nagai
-
Patent number: 3996522Abstract: A signal-seeking radio receiver is disclosed which has two different types of local oscillator circuits. One type of local oscillator includes two transistors, the emitter of the first connecting to the base of the second and having a capacitor connecting between the emitter of the second and the base of the first. A large number of diode switched crystals can be connected to the base of the first transistor of the local oscillator without introducing an instability in the oscillator circuit. The second type of local oscillator is of the same general design as the first type except that it additionally includes a third transistor connected to the second transistor in a fashion similar to the first transistor. In this second oscillator configuration, the circuitry used to step among the channels also is used to alternately make either the first or third transistor operative in the local oscillator circuit.Type: GrantFiled: November 17, 1975Date of Patent: December 7, 1976Assignee: Regency Electronics Inc.Inventors: Richard C. Koch, Stephen J. Hoffman